Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.54 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695588 | 1.00 | OPRD1 (0.54) | OPRD1IL23RC5AR1KEAP1EPHA2 | |
| SCHEMBL29403705 | 0.97 | IL23R (0.55) | OPRD1IL23RC5AR1EPHA2 | |
| SCHEMBL6889227 | 0.95 | OPRD1 (0.54) | OPRD1IL23RC5AR1 | |
| SCHEMBL6889257 | 0.95 | OPRD1 (0.54) | OPRD1IL23RC5AR1 | |
| SCHEMBL31078160 | 0.93 | OPRD1 (0.54) | OPRD1IL23RC5AR1KEAP1 | |
| SCHEMBL30483821 | 0.93 | OPRD1 (0.54) | OPRD1IL23RC5AR1KEAP1 | |
| SCHEMBL29583466 | 0.92 | OPRD1 (0.64) | OPRD1 | |
| SCHEMBL30483833 | 0.91 | OPRD1 (0.52) | OPRD1C5AR1KEAP1EPHA2 | |
| SCHEMBL30605203 | 0.89 | OPRD1 (0.52) | OPRD1IL23RC5AR1 | |
| SCHEMBL31267098 | 0.88 | EPHA2 (0.53) | OPRD1IL23REPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642492-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| WO-2024240173-A1 | AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| CN-112672763-B | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2025-03-25 | — | — | CN | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| EP-4408480-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118043084-A | Compositions and methods for metal-containing formulations capable of modulating immune responses | 密执安大学评议会 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023056427-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-01-26 | — | — | US | disclosed |
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072023-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | OPRD1 4808/4885IL23R 809/4885C5AR1 67/4885 |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | OPRD1 4808/4885IL23R 809/4885C5AR1 67/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | OPRD1 2595/4885IL23R 357/4885C5AR1 21/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | OPRD1 4324/4885IL23R 1055/4885C5AR1 1518/4885 |
| US-20230025865-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS | BCL2, BCL2L2, BCL2L1 | OPRD1 4510/4885IL23R 751/4885C5AR1 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.